<DOC>
	<DOCNO>NCT00428519</DOCNO>
	<brief_summary>The investigator ' vitro data suggest Neurokinin-1 receptor antagonist like aprepitant decrease expression CCR5 , essential co-receptor life cycle HIV , surface macrophage lymphocytes level least similar observe patient heterozygous CCR5 32 mutation . Together direct potential antiviral effect could alter disease progression patient HIV infection . The investigator ' hypothesis aprepitant safe , tolerable antiviral activity HIV infect individual . This randomized , placebo control , double blind study determine safety antiviral activity aprepitant comparing change HIV RNA viral load 2 week aprepitant monotherapy . 27 HIV infect male female ≥ 18 year old early infection CD4 cell count ≥ 350 cells/mm3 . Subjects randomize 1:1:1 receive two different dos aprepitant ( Emend® ) placebo .</brief_summary>
	<brief_title>Effects Treatment With Aprepitant ( Emend® ) HIV Infected Individuals</brief_title>
	<detailed_description>DESIGN Randomized , placebo control , double blind study determine safety antiviral activity aprepitant comparing change HIV RNA viral load 2 week aprepitant monotherapy . DURATION 42 day . SAMPLE SIZE POPULATION 27 HIV infect male female ≥ 18 year old early infection CD4 cell count ≥ 350 cells/mm3 . REGIMEN Subjects randomize 1:1:1 receive two different dos aprepitant ( Emend® ) placebo . - Arm A : Aprepitant placebo - Arm B : Aprepitant 125 mg QD - Arm C : Aprepitant 250 mg QD HYPOTHESIS AND STUDY OBJECTIVES - Hypothesis : Aprepitant safe , tolerable , antiviral activity HIV infect individual . - Primary Objectives : - To assess safety tolerability aprepitant 2 week two different dos . - To assess response plasma HIV-1 RNA two different dos aprepitant compare baseline . - Secondary Objectives : - To investigate course duration antiretroviral response 2 different dos aprepitant give 14-day period . - To evaluate dose-response pharmacokinetic pharmacodynamic relationship viral RNA change aprepitant plasma level . - To evaluate aprepitant effect CD4+ CD8+ T-cell count , circulate SP level , natural killer cell number function CCR5 expression peripheral PBMCs . - To evaluate effect aprepitant viral tropism envelope sequence main HIV-1 population participant . - To assess viral drug susceptibility conjunction baseline coreceptor tropism phenotype change coreceptor phenotype exposure aprepitant . - To evaluate aprepitant effect fast plasma glucose , insulin , HDL , free fatty acid , triglyceride concentration 14 day treatment . - To provide preliminary description change baseline sleep quality , anxious mood , depress mood neurocognitive measure 2 week aprepitant therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>1 . HIV1 infection , document licensed ELISA test kit confirm Western blot time prior study entry . HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test . 2 . CD4+ cell count ≥ 350/mm3 obtain within 90 day prior study entry perform CLIAcertified laboratory . 3 . Plasma HIV1 RNA ≥ 2000 copies/mL measure standard assay ( Roche UltraSensitive HIV1 Monitor assay ( Roche Molecular Systems ) , Version 3 bDNA assay ) perform within 90 day prior study entry laboratory CLIAcertified ( equivalent ) assay . 4 . CCR5 tropic virus exclusively determine Monogram tropism assay ( PhenoSense Entry™ ) . 5 . Laboratory value obtain within 30 day prior study entry , follow : Absolute neutrophil count ( ANC ) great 750/mm3 Hemoglobin great 10.0 g/dL Platelet count great 100,000/mm3 Creatinine less 2 x ULN ( fast ) AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase le 2 x ULN Total bilirubin le 2.5 x ULN Albumin great 3 g/dL Serum lipase le 1.5 x ULN 6 . Female subject reproductive potential must negative spot urine pregnancy test result ( sensitivity least 50 mIU/mL ) perform entry , prior start initial study treatment . 7 . All subject must agree participate conception process study drug 30 day stop medication . If participate sexual activity could lead pregnancy , female study subject must use least one form contraception list receive protocolspecified medication 30 day stop medication : Condoms ( male female ) without spermicidal agent Diaphragm cervical cap spermicide IUD Female subject , reproductive potential define woman postmenopausal least 24 consecutive month , woman undergo surgical sterilization , ( e.g . hysterectomy , bilateral oophorectomy , salpingotomy ) eligible without require use contraception . Subject report history acceptable documentation sterilization , contraceptive method , menopause child 's reproductive potential . 8 . Karnofsky performance score great 80 within 30 day prior study entry . 9 . Men woman great 18 year age . 10 . Ability willingness subject legal guardian/representative give write informed consent . 11 . Willing return followup visit day 42 . 12 . Subjects take precautionary concomitant medication must stable dos &gt; 8 week prior study entry plan change medication dos duration study . 1 . Receipt antiretroviral treatment within 16 week prior study entry intent initiate antiretroviral therapy within 60 day entry . 2 . Diabetes require treatment oral hypoglycemics insulin therapy . 3 . Pregnancy within 90 day prior study entry . 4 . Breastfeeding . 5 . Use drug inhibitor inducer metabolism cytochrome P450 CYP3A4 CYP2C9 ( warfarin phenytoin ) within 7 day study entry . 6 . Use systemic corticosteroid hormonal agent within 90 day prior study entry . 7 . Use immunomodulator , HIV vaccine , investigational therapy within 90 day prior study entry . 8 . Any vaccination within 30 day prior study entry . 9 . Use systemic cytotoxic chemotherapy within 90 day prior study entry . 10 . History allergy aprepitant formulation . 11 . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . 12 . History chronic active hepatitis B C infection severe hepatic dysfunction ( ChildPlug score &gt; 9 ) regardless etiology . 13 . Serious illness require systemic treatment and/or hospitalization subject either complete therapy clinically stable therapy , opinion investigator , least 14 day prior study entry . 14 . Weight &lt; 40 kg 88 lb within 90 day prior study entry . 15 . History severe psychiatric comorbidities , depression , schizophrenia , mania , psychosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Neurokinin-1 receptor antagonist</keyword>
	<keyword>CCR5 expression</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>